Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - AZIYO BIOLOGICS, INC. | tm214229d1_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - AZIYO BIOLOGICS, INC. | tm214229d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - AZIYO BIOLOGICS, INC. | tm214229d1_ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - AZIYO BIOLOGICS, INC. | tm214229d1_ex23-1.htm |
| EX-21.1 - EXHIBIT 21.1 - AZIYO BIOLOGICS, INC. | tm214229d1_ex21-1.htm |
| EX-4.4 - EXIBIT 4.4 - AZIYO BIOLOGICS, INC. | tm214229d1_ex4-4.htm |
| 10-K - FORM 10-K - AZIYO BIOLOGICS, INC. | tm214229d1_10k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Aziyo Biologics, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: March 15, 2021 | By: | /s/ Ronald Lloyd | |
| Ronald Lloyd | |||
|
President and Chief Executive Officer (principal executive officer) |
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.